Overview

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

Status:
Completed

Trial end date:
2016-12-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if Vibativ (telavancin) can help to control blood stream infections (BSIs). The safety of this treatment will also be studied. Objectives: Evaluate the clinical efficacy and safety of Telavancin given for treatment of gram positive bacteremia in cancer patients (including neutropenics).

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborators:

Theravance Biopharma
Theravance Biopharma Antibiotics, Inc.

Treatments:

Telavancin